13 April 2023 - - US-based for-profit corporation VasoCorp, with a goal to change the standard of care for those suffering from neuropathic discomfort by proving the efficacy of a dietary supplement formula, has released the results from their Phase I clinical trial, the company said.

The trial was authored by William Cross, president and Founder of VasoCorp, and Dr. Shalini` Srivastava, director, Vedic Life Sciences, Mumbai, India.

Cross has a record of research on innovative ideas and basic science discoveries. In 2017, Cross was awarded Young Entrepreneur of the Year by the US Small Business Administration's Georgia District Office who acknowledge that his "efforts...have helped thousands of people ease their debilitating pain."

The study was conducted under supervision of Dr. Shalini` Srivastava, Vedic Life Sciences, Mumbai, India.

The primary objective of the study was to evaluate the effects of a dietary Nerve Support Formula on diabetic neuropathic pain.

The results of the study were significant and could have profound, life-changing impacts on the health and wellness of those suffering from nerve discomfort.

Cross has recently updated VasoCorp's portfolio of products with similar novel formulas that support Kidney and Eye health.

VasoCorp is a vitamin supplement company founded in 2016. VasoCorp's NeuropAWAY Brand products are focused on the diabetes health market, the aging population, and the health and wellness market.

VasoCorp's patented and patent pending formulas offer a new approach to managing occasional nerve aches, and an alternative to opioids.

Vedic Lifesciences is a contract research organization, that has completed more than 400 clinical and preclinical studies in compliance with international regulations.

Vedic Lifesciences is among the few GCP-compliant CROs that are fully aligned with the FDA and FTC standards for human studies.